Amalia Lafuente-rekin lankidetzan egindako argitalpenak (8)

2020

  1. Association study of candidate genes with obesity and metabolic traits in antipsychotic-treated patients with first-episode psychosis over a 2-year period

    Journal of Psychopharmacology, Vol. 34, Núm. 5, pp. 514-523

  2. Personalized medicine begins with the phenotype: identifying antipsychotic response phenotypes in a first-episode psychosis cohort

    Acta Psychiatrica Scandinavica, Vol. 141, Núm. 6, pp. 541-552

2019

  1. Gene-environment interaction between an endocannabinoid system genetic polymorphism and cannabis use in first episode of psychosis

    European Neuropsychopharmacology, Vol. 29, Núm. 6, pp. 786-794

2018

  1. Impact of NTRK2, DRD2 and ACE polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis

    Journal of Psychopharmacology, Vol. 32, Núm. 6, pp. 702-710

2017

  1. Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients

    European Neuropsychopharmacology, Vol. 27, Núm. 7, pp. 647-656

2016

  1. A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project

    International Journal of Neuropsychopharmacology, Vol. 19, Núm. 4

  2. Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: Role of dopamine, serotonin and glutamate candidate genes

    Pharmacogenomics Journal, Vol. 16, Núm. 5, pp. 439-445

2014

  1. Pro-/anti-inflammatory dysregulation in patients with first episode of psychosis: Toward an integrative inflammatory hypothesis of schizophrenia

    Schizophrenia Bulletin, Vol. 40, Núm. 2, pp. 376-387